{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:02:46Z","timestamp":1777399366299,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017242","name":"National Institutes for Food and Drug Control","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017242","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.vaccine.2024.03.044","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T21:29:31Z","timestamp":1711056571000},"page":"2858-2866","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A randomized, blind, parallel controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2\u00a0years and older"],"prefix":"10.1016","volume":"42","author":[{"given":"Yuhui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangfu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiebing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenna","family":"Leng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Zong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaocan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongyang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youcai","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaodong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.03.044_b0005","unstructured":"Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococc-al infection in adults. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD000422. doi: 10.1002\/14651858.CD000422.pub2. Update in: Cochrane Database Syst Rev. 2013;1:CD000422. PMID: 18253977."},{"issue":"123","key":"10.1016\/j.vaccine.2024.03.044_b0010","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1183\/09059180.00008911","article-title":"The remaining challenges of pne-umococcal disease in adults","volume":"21","author":"Ludwig","year":"2012","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.vaccine.2024.03.044_b0015","first-page":"373","article-title":"23-valent pneumococcal polysaccharide vaccine: WHO position paper","volume":"83","author":"World Health Organization","year":"2008","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2024.03.044_b0020","unstructured":"Dion CF, Ashurst JV. Streptococcus pneumoniae. 2022 Aug 8. In: StatPearls [Internet]. T-reasure Island (FL): StatPearls Publishing; 2023 Jan\u2013. PMID: 29261971."},{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2024.03.044_b0025","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1469-0691.2012.03937.x","article-title":"Understanding the burden of pneumococcal dise-ase in adults","volume":"18","author":"Blasi","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2024.03.044_b0030","doi-asserted-by":"crossref","unstructured":"Alanee SR, McGee L, Jackson D, Chiou CC, Feldman C, Morris AJ, Ortqvist A, Rello- J, Luna CM, Baddour LM, Ip M, Yu VL, Klugman KP; International Pneumococcal Study Group. Association of serotypes of Streptococcus pneumoniae with disease severity and outc-ome in adults: an international study. Clin Infect Dis. 2007 Jul 1;45(1):46-51. doi: 10.1086\/518538. Epub 2007 May 31. PMID: 17554699.","DOI":"10.1086\/518538"},{"issue":"10","key":"10.1016\/j.vaccine.2024.03.044_b0035","doi-asserted-by":"crossref","first-page":"e1000348","DOI":"10.1371\/journal.pmed.1000348","article-title":"Systematic evaluation of serotypes causing invasive pneumococc-al disease among children under five: the pneumococcal global serotype project","volume":"7","author":"Johnson","year":"2010","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.vaccine.2024.03.044_b0040","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1128\/JCM.43.3.1285-1293.2005","article-title":"Trends in drug resistance, serotypes, and molecular types of st-reptococcus pneumoniae colonizing preschool-age children attending day care centers in Lisbon, Portugal: a summary of 4 years of annual surveillance","volume":"43","author":"Nunes","year":"2005","journal-title":"J Clin Microbiol"},{"issue":"Pt 2","key":"10.1016\/j.vaccine.2024.03.044_b0045","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1099\/jmm.0.47470-0","article-title":"Prevalence and risk factors for nasopharyngeal carriage of Streptococcus pneumoniae among adolescents","volume":"57","author":"Cardozo","year":"2008","journal-title":"J Med Microbiol"},{"issue":"35","key":"10.1016\/j.vaccine.2024.03.044_b0050","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1016\/j.vaccine.2008.06.052","article-title":"Streptococcus pneumoniae diseases in chinese children: past, present and future","volume":"26","author":"Yao","year":"2008","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2024.03.044_b0055","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1086\/431521","article-title":"Active bacterial Core surveillance program of the Emerging infections program network. the infl-uence of chronic illnesses on the incidence of invasive pneumococcal disease in adults","volume":"192","author":"Kyaw","year":"2005","journal-title":"J In-fect Dis"},{"issue":"48 Suppl 2","key":"10.1016\/j.vaccine.2024.03.044_b0060","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1086\/596485","article-title":"Pneumococcal study group. multihospital surveillance of pneumonia burden among chi-ldren aged <5 years hospitalized for pneumonia in Bangladesh","volume":"1","author":"Naheed","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.044_b0065","doi-asserted-by":"crossref","unstructured":"Harboe ZB, Thomsen RW, Riis A, Valentiner-Branth P, Christensen JJ, Lambertsen L, Krogfelt KA, Konradsen HB, Benfield TL. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med. 2009 May 26;6(5):e1000081. doi: 10.1371\/journal.pmed.1000081. Epub 2009 May 26. PMID: 19468297; PMCI-D: PMC2680036.","DOI":"10.1371\/journal.pmed.1000081"},{"key":"10.1016\/j.vaccine.2024.03.044_b0070","article-title":"Circulating antibody secreting cell resp-onse to parenteral pneumococcal vaccines as an indicator of a salivary IgA antibody respons-e","author":"Nieminen","year":"1998","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2024.03.044_b0075","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1164\/rccm.202004-1483OC","article-title":"Expe-rimental human pneumococcal colonization in older adults is feasible and safe, not immunogenic","volume":"203","author":"Adler","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.vaccine.2024.03.044_b0080","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.3390\/vaccines9111338","article-title":"Pneumococcal vaccines: past fi-ndings, present work, and future strategies","volume":"9","author":"Oliveira","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"9","key":"10.1016\/j.vaccine.2024.03.044_b0085","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(07)70210-4","article-title":"Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?","volume":"7","author":"O'Brien","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.044_b0090","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1742-4933-2-10","article-title":"Immune response to pneumococcal po-lysaccharides 4 and 14 in elderly and young adults. I antibody concentrations, avidity and functional activity","volume":"2","author":"Kolibab","year":"2005","journal-title":"Immun Ageing"},{"issue":"13","key":"10.1016\/j.vaccine.2024.03.044_b0095","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1001\/archinte.160.13.2017","article-title":"Immune function and vaccine res-ponses in healthy advanced elderly patients","volume":"160","author":"Carson","year":"2000","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.vaccine.2024.03.044_b0100","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1128\/CMR.16.2.308-318.2003","article-title":"Pneumococcal vaccination and revaccination of older adults","volume":"16","author":"Artz","year":"2003","journal-title":"Clin Microbiol Rev"},{"issue":"16","key":"10.1016\/j.vaccine.2024.03.044_b0105","first-page":"1533","article-title":"Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in healthy children and in children at increased risk of pneumococcal infection","volume":"13","author":"Lee","year":"1995","journal-title":"Vac-cine"},{"issue":"12","key":"10.1016\/j.vaccine.2024.03.044_b0110","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.rmed.2011.07.008","article-title":"Pneumococcal vaccination in adults: does it really work?","volume":"105","author":"Pitsiou","year":"2011","journal-title":"Resp-ir Med"},{"issue":"11","key":"10.1016\/j.vaccine.2024.03.044_b0115","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1097\/INF.0000000000001288","article-title":"Cost-effectiveness and health benefits of pediatric 23-valent pneumococcal Polysaccharide vaccine, 7-valent pneumococcal conjugate vaccine and forecasting 13-valent pneumococcal conjugate vaccine in China","volume":"35","author":"Mo","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2024.03.044_b0120","series-title":"Training manual for enzyme-linked immunosorbent assay for the quantitation of Streptococcus pneumoniae serotype specific IgG (pn PS ELISA)(WHO13)","author":"World Health Organization","year":"2004"},{"key":"10.1016\/j.vaccine.2024.03.044_b0125","doi-asserted-by":"crossref","unstructured":"Feldman C, Anderson R. Recent advances in the epidemiologyandpreventionof Streptoco-ccus pneumoniaeinfections[J].F1000Res, 2020, 9:F1000 Faculty Rev-338.DOI:10.12688\/f1000r-esearch.22341.1.","DOI":"10.12688\/f1000research.22341.1"},{"key":"10.1016\/j.vaccine.2024.03.044_b0130","doi-asserted-by":"crossref","unstructured":"Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD000422. doi: 10.1002\/14651858.CD000422.pub3. PMID: 23440780; PMCID: PMC7045867.","DOI":"10.1002\/14651858.CD000422.pub3"},{"issue":"10","key":"10.1016\/j.vaccine.2024.03.044_b0135","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1080\/21645515.2015.1055429","article-title":"Immunogenicity and safety of a 23-valent pn-eumococcal polysaccharide vaccine in chinese healthy population aged > 2 years:a random-ized, double-blinded, active control, phase III trial [J]","volume":"11","author":"Kong","year":"2015","journal-title":"Human Vaccines & Immunotherapeuti-cs"},{"issue":"3","key":"10.1016\/j.vaccine.2024.03.044_b0140","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1080\/21645515.2015.1011015","article-title":"Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in 2 to 70 year old healthy people in China: a phase III double blind, randomized clinical trial","volume":"11","author":"Guifan","year":"2015","journal-title":"Hum Vacc Im-munother"},{"key":"10.1016\/j.vaccine.2024.03.044_b0145","doi-asserted-by":"crossref","unstructured":"Huang L, Wang L, Li H, Hu Y, Ru W, Han W, Shi G, Ye Q, Han Z, Xia J, Xia S, Xu M, Li J. A phase III clinical trial to evaluate the safety and immunogenicity of 23-vale-nt pneumococcal polysaccharide vaccine (PPV23) in healthy children, adults, and elderly. Hum Vaccin Immunother. 2019;15(1):249-255. doi: 10.1080\/21645515.2018.1509648. Epub 2018 Sep 21. PMID: 30215583; PMCID: PMC6363133.","DOI":"10.1080\/21645515.2018.1509648"},{"key":"10.1016\/j.vaccine.2024.03.044_b0150","unstructured":"Chinese Preventive Medicine Association; Vaccine and Immunology Branch of the Chin-ese Preventive Medicine Association. [Expert consensus on immunoprophylaxis of pneumoco-ccal disease (2020 version)]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Dec 10;41(12):1945-1979. Chinese. doi: 10.3760\/cma.j.cn112338-20201111-01322. PMID: 33261246."},{"issue":"14","key":"10.1016\/j.vaccine.2024.03.044_b0155","first-page":"129","article-title":"Pneumococcal vaccines WHO position paper-2012[J]","volume":"87","author":"Who","year":"2012","journal-title":"Weekly Epidemiological R-ecord"},{"key":"10.1016\/j.vaccine.2024.03.044_b0160","first-page":"390","article-title":"Clinical effect of 23-valent pneumococcal Polysaccharide vaccine","volume":"4","author":"Yang","year":"2007","journal-title":"J Prev Med Infor"},{"issue":"4","key":"10.1016\/j.vaccine.2024.03.044_b0165","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1086\/649839","article-title":"Safety and antibody response, including antibody persistencefor 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide va-ccine in middle-aged and older adults","volume":"201","author":"Musher","year":"2010","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24003311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24003311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T04:16:20Z","timestamp":1712981780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24003311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0264410X24003311"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.044","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized, blind, parallel controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2\u00a0years and older","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}